Guidance will compel sponsors to consider new enrollment strategies and to be more diverse.
Marjorie E. Zettler, PhD, MPH
Advertisement
Executive Director of Clinical Science, Regor Pharmaceuticals, Inc.
Articles by Marjorie E. Zettler, PhD, MPH
Advertisement
Latest Updated Articles
FDA’s New Diversity Plan Guidance, And What It Means for Sponsors Developing Cancer DrugsPublished: June 9th 2022 | Updated:
Advertisement
Advertisement
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
